Chris Byrne, United Kingdom
University of Southampton, UK Nutrition and Metabolism, Faculty of MedicinePresenter of 1 Presentation
NAFLD/NASH in metabolic syndrome and early type 2 diabetes
Abstract
Abstract Body
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disease that is strongly associated with obesity, type 2 diabetes (T2DM) and other metabolic and vascular risk factors. It is now established that NAFLD is a multisystem disease with consequences beyond the liver. NAFLD increases risk of many extra-hepatic diseases such as cardiovascular disease (CVD), chronic kidney disease (CKD) and certain cancers. NAFLD encompasses a spectrum of lipid-associated liver disease and in affected individuals NAFLD may progress from simple steatosis to steatohepatitis, liver fibrosis and cirrhosis. This presentation will discuss the relationships between NAFLD and type 2 diabetes that form part of a vicious cycle of spiralling and worsening metabolic disease. Not only does NAFLD increase risk of developing diabetes with insulin resistance and poor glycaemic control, but development of diabetes further increases risk of worsening liver disease, liver fibrosis and hepatocellular carcinoma. Relationships between NAFLD and cardiovascular disease and the modifying influence on cardiovascular disease of certain genotypes known to increase severity of liver disease will also be discussed.